清心解瘀方治疗稳定性冠心病疗效观察及对ANK1、CD40L 的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.4

基金项目:

河南省中医管理局国家中医临床研究基地科研专项项目(2018JDZX101)


Clinical Observation on Curative Effect of Qingxin Jieyu Prescription on Stable Coronary Heart Disease and Its Effect on ANK1 and CD40L
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察清心解瘀方治疗稳定性冠心病的疗效及对细胞锚蛋白1(ANK1)、血清CD40 配体(CD40L) 的影响。方法:将稳定性冠心病患者134 例分为2 组。对照组在常规治疗基础上加服安慰剂,观察组在常规治疗基础上加服清心解瘀方治疗,分析2 组患者治疗后的临床疗效及临床结局,监测ANK1、CD40L、角蛋白8(KRT8)。结果:观察组总有效率为80.60%,高于对照组的64.18%,差异有统计学意义(P<0.05)。治疗前,2 组ANK1、CD40L、KRT8 水平比较,差异无统计学意义(P>0.05)。2 组治疗后均较前改善,观察组治疗后ANK1、CD40L、KRT8 水平低于对照组(P<0.05)。观察组主要复合终点事件发生率1.49%,低于对照组的10.45%,2 组比较,差异有统计学意义(P<0.05)。观察组次要复合终点事件发生率为1.49%,与对照组(4.48%) 比较,差异无统计学意义(P>0.05)。结论:清心解瘀方治疗稳定性冠心病可调节患者体内ANK1、CD40L、KRT8 的表达水平,降低患者终点事件发生率,提高疗效。

    Abstract:

    effect on ankyrin 1(ANK1) and CD40 ligand(CD40L). Methods:A total of 134 patients with stable coronary heart disease were divided into two groups. The control group was treated with placebo based on conventional treatment, and the observation group was treated with Qingxin Jieyu prescription based on conventional treatment. The clinical effect and outcome of the two groups were analyzed,and the levels of ANK1, CD40L and keratin 8(KRT8) were monitored. Results: The total effective rate was 80.60% in the observation group, higher than that of 64.18% in the control group,the difference being significant(P<0.05). Before treatment, there was no significant difference in the comparison of the levels of ANK1, CD40L and KRT8 between the two groups(P>0.05). The levels of ANK1, CD40L and KRT8 in both groups were improved when respectively compared with those before treatment, and those in the observation group were lower than those in the control group(P<0.05). The incidence of major composite endpoint events was 1.49% in the observation group, lower than that of 10.45% in the control group(P<0.05). The incidence of secondary composite endpoint events was 1.49% in the observation group, lower than that of 4.48% in the control group, there being no significant difference(P>0.05). Conclusion: Qingxin Jieyu prescription for stable coronary heart disease, can regulate the expression levels of ANK1, CD40L and KRT8 in patients, reduce the incidence of composite endpoint events, and improve the curative effect.

    参考文献
    相似文献
    引证文献
引用本文

王贞,张志国,张君.清心解瘀方治疗稳定性冠心病疗效观察及对ANK1、CD40L 的影响[J].新中医,2020,52(17):51-54

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-09-06
  • 出版日期: